Where can I find the specific financial results for Regeneron's first quarter of 2015?

The specific financial and operating results for the first quarter ended March 31, 2015, are detailed in the press release dated May 7, 2015, which is furnished as Exhibit 99.1 to this 8-K filing. You should refer to that document for detailed information.

What is the significance of this 8-K filing?

This 8-K filing is significant as it formally notifies the SEC and the public that Regeneron has released its quarterly earnings and operational update. It directs investors to the comprehensive information contained within the accompanying press release.

Does this filing include forward-looking statements or guidance from Regeneron?

This 8-K filing itself does not contain forward-looking statements or specific guidance. However, the press release it references (Exhibit 99.1) typically includes such information, which investors should review for potential future performance outlooks.

Is the information in the furnished press release legally considered 'filed' with the SEC?

No, according to the filing, the information included or incorporated from the press release (Exhibit 99.1) is furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any registration statement under the Securities Act of 1933, unless expressly stated otherwise.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 7, 2015, primarily to furnish its press release detailing its financial and operating results for the first quarter ended March 31, 2015. While the filing itself does not contain detailed financial figures, it serves as a notification to investors that the company has publicly released its quarterly performance. Investors should refer to the furnished press release (Exhibit 99.1) for specific information regarding revenue, earnings, pipeline updates, and strategic developments during the first quarter of 2015. This report is a standard procedural filing, with the substantive investor information contained within the referenced press release.

Key Highlights

1Company announced first quarter 2015 financial and operating results on May 7, 2015.
2The 8-K filing primarily serves to furnish the official press release detailing these results.
3Investors should consult the press release (Exhibit 99.1) for detailed financial and operational data.
4This filing does not contain substantive financial information directly but references its public disclosure.
5The information is furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 7, 2015)

Summary

Key Highlights

Frequently Asked Questions